This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
If You Invested $1000 in Idexx Laboratories 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in CAG diagnostics business and the recent ezyVet buyout are likely to have contributed to growth for IDEXX (IDXX).
Idexx Laboratories (IDXX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $651.96, moving -0.09% from the previous trading session.
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Why Idexx (IDXX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.
Hologic (HOLX) Adds New Products to Omni Hysteroscopy Offering
by Zacks Equity Research
Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.
Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle
by Zacks Equity Research
Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.
Petco (WOOF) Down 26% This Year So Far: What Should You Do?
by Zacks Equity Research
Petco (WOOF) with its omni-channel distribution and a well-diversified product offering is strongly placed in the pet care industry, which is growing rapidly.
Thermo Fisher (TMO) Launches Kit for Safer Sample Collection
by Zacks Equity Research
Thermo Fisher (TMO) launches SpeciMAX Stabilized Saliva Collection Kit that can support global efforts toward SARS-CoV-2 research by ensuring safer saliva collection.
Veeva Systems' (VEEV) New Offering to Optimize Lab Operations
by Zacks Equity Research
Veeva Systems' (VEEV) Vault LIMS is expected to help manufacturers optimize lab management and significantly simplify their systems landscape via a unified suite of quality and lab applications.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study
by Zacks Equity Research
Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.
Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS
by Zacks Equity Research
According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.
Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants
by Zacks Equity Research
Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.
NEOGEN (NEOG) Igenity Branded Calves Score Highest US Sales
by Zacks Equity Research
NEOGEN's (NEOG) Igenity-tested calves earn an average premium of over $59 in the summer selling season.
IDEXX (IDXX) CAG Placement Grows Globally Amid Cost Woes
by Zacks Equity Research
IDEXX's (IDXX) global reference lab revenues are growing organically, reflecting growth in the United States and the international markets.
Thermo Fisher's (TMO) Delta Q IRMS to Back Sustainable Science
by Zacks Equity Research
Thermo Fisher (TMO) has introduced the new Delta Q IRMS under the IsoFootprint campaign to support sustainable science by eliminating carbon dioxide emission.
Baxter's (BAX) Premix Norepinephrine Now Available in U.S.
by Zacks Equity Research
Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.